ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO889

Infection Rates in ESRD and Renal Transplant Patients Using Real World Claims Data

Session Information

  • Dialysis: Infection
    November 02, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 610 Dialysis: Infection

Authors

  • Belendiuk, Katherine, Genentech, Inc., South San Francisco, California, United States
  • Rajwanshi, Richa, Genentech, Inc., South San Francisco, California, United States
  • Ding, Yingjie, Genesis Research, Hoboken, New Jersey, United States
  • Kwon, Kelly, Genentech, Inc., South San Francisco, California, United States
  • Borie, Dominic, Genentech, Inc., South San Francisco, California, United States
  • Cascino, Matthew, Genentech, Inc., South San Francisco, California, United States
  • Garg, Jay P., Genentech, Inc., South San Francisco, California, United States
  • Schindler, Thomas, F. Hoffmann - La Roche Ltd., Basel, Switzerland
  • Tran, Ha N., Genentech, Inc., South San Francisco, California, United States
Background

End stage renal disease (ESRD) patients (pts) are at increased risk of infections due to immune dysregulation, malnutrition, and indwelling dialysis access. After transplant (tx), pts are at further risk due to immunosuppressive therapy. Characterization of infections in large, real world samples will allow clinicians to better evaluate and understand infection risks in their patients. The objective of this study was to characterize the rates of serious and opportunistic infections in ESRD and renal tx pts.

Methods

We conducted a retrospective cohort study using the Truven Healthcare MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits database between 2000 and 2014. The ESRD cohort index date was the first of either an ESRD or dialysis claim, separated by ≥7 days. The tx cohort index date was the first of ≥2 claims related to kidney tx, separated by ≥7 days.

Results

23,433 ESRD pts on dialysis and 18,660 renal tx pts were identified. One year following the index date, the rates of serious infections were higher in ESRD than tx pts. Most serious infections required hospitalization in both groups and opportunistic infection rates were comparable (Table 1).

Conclusion

ESRD and post-tx pts experience serious infections with high rates of hospitalization indicating high burden of illness. Physicians should carefully evaluate infection risks when considering pre- and post-tx immunosuppressive regimens.

Funding

  • Commercial Support